Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial

Shifting the Narrative of Preexposure Prophylaxis Adherence Counseling for Cisgender Women

“…Unfortunately, despite the reassuring finding by Marrazzo et al of high protection among those consistently taking at least 4 doses per week, less than 40% of participants achieved this benchmark and had dramatic declines in adherence by 96 weeks. The percentage of participants with sustained adherence was much lower than in previous studies in MSM, underscoring the challenge of daily oral F/TDF for cisgender women. Barriers to PrEP adherence may vary by local context, although low perception of HIV risk, stigma, and poor social support are among the common reasons across settings .…”

In Situ Forming, Enzyme-Responsive Peptoid-Peptide Hydrogels: An Advanced Long-Acting Injectable Drug Delivery System

“…There is also an urgent need for more discrete HIV/AIDS treatment and prevention strategies, with several at-risk groups preferring long-acting formulations, including injections, to daily dosing with tablet(s). , In January 2021, ViiV Healthcare’s Cabenuva (rilpivirine, cabotegravir) became the first Food and Drug Administration (FDA)-approved intramuscular long-acting injectable for HIV treatment in adults . This was shortly followed by the licensing of long-acting Apretude (cabotegravir) suspension for HIV prevention in at-risk groups because of its superiority compared to daily oral PrEP in reducing HIV incidence in randomized clinical trials (HIV Prevention Trials Network [HPTN] 083 and HPTN 084) …”

“…42 This was shortly followed by the licensing of long-acting Apretude (cabotegravir) suspension for HIV prevention in at-risk groups because of its superiority compared to daily oral PrEP in reducing HIV incidence in randomized clinical trials (HIV Prevention Trials Network [HPTN] 083 and HPTN 084). 43 The development of long-acting formulations tends to focus on the use of: water-insoluble drugs as suspensions in which drug particles are suspended in an aqueous medium; 44 microspheres were drugs are encapsulated within biodegradable polymers; 45 oil-based injections whereby hydrophobic drugs are dissolved in an oily medium and precipitate upon injection; 46 or preformed implants composed of nonbiodegradable polymers. 47 there are several challenges to their wider use as long-acting drug delivery platforms.…”